Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment
Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Read More
Triple Combination Therapies in RCC: Clinical Trial Insights
Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Read More
Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Read More
Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma
Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.
Read More
Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC
Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).
Read More
Sequencing and Second-Line Therapy in RCC: Patient Scenario
Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.
Read More
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
Read More
Comparing Treatment Combinations in Renal Cell Carcinoma
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Read More
Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma
Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
Read More
Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Read More
Imaging and Staging Considerations in Renal Cell Carcinoma
Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.
Read More
Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion
Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.
Read More
Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification
Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
Read More
Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC
July 26th 2023Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Read More
Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer
July 10th 2023Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.
Read More
Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC
July 6th 2023Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
Read More